LGVN News and Press, Longeveron Inc. From 07/25/21

Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m. on Seeking Alpha, iTunes, Stitcher and Spotify. Economic reports in the week ahead Tech heavyweights will be in the spotlight next week with Apple (NASDAQ:AAPL), Microsoft (NASDAQ:MSFT), Alphabet (NASDAQ...

knowlesgallery/iStock via Getty Images The Alzheimer's Association International Conference begins Monday and runs through July 30 both in person in Denver and online. As always, there are several eagerly awaited presentations from companies working on Alzheimer's therapies that could lead to...

solarseven/iStock via Getty Images Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calenda...

• Multicenter, double-blinded, controlled study designed to evaluate safety & efficacy of Lomecel-B intramyocardial injection in infants with HLHS • Funded by the National Heart, Lung and Blood Institute (Grant number 1UG3HL148318 and 1U24HL148316) in coll...

MIAMI, June 30, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN) ("Longeveron" or "Company"), a clinical stage biotechnology company developing cellular therapies for chronic, aging-related and life-threatening conditions, today announced that two abstracts for Lomecel-B, the Co...

Palm Beach, FL – June 24, 2021 – According to the Centers for Disease Control and Prevention, Alzheimer’s is among the top 10 leading causes of deaths in the United States. The death rate for the disease has increased significantly in the U.S. over the past few years. M...

Marin Software Incorporated (MRIN) +63% on new InstaCart Ad Integration.India Globalization Capital (IGC) +22% on Alzheimer’s drug trial update.GTT Communications (GTT) +21%.Aravive, Inc. (ARAV) +20% on early-stage kidney cancer study data.Arcus Biosciences (RCUS) +19%&#...

MIAMI, June 24, 2021 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing cellular therapies for aging-related and chronic disease, announced today that an abstract summarizing the results of its Phase 1 trial of Lomecel-B infusion for patien...

Featuring Avalon GloboCare (AVCO), Caladrius Biosciences (CLBS), Celularity, ImmCelz / Creative Medical Technology Holdings (CELZ), ExoProTher, GID BIO, HealthLynked (HLYK), Longeveron (LGVN), Mesoblast (MESO) - Presented by Channelchek and Noble Capital Markets Read More >>

Longeveron CEO Geoff Green - The Investor Forum at the World Stem Cell Summit. Each presentation features a formal corporate overview, followed by a Q & A session moderated by a Noble Capital Markets equity research representative. Read More >>